A new cancer treatment recently approved in Canada promises to cut treatment time down to just minutes, but experts have differing opinions on whether it s what s best for patients.
A new cancer treatment recently approved in Canada promises to cut treatment time down to just minutes, but experts have differing opinions on whether it s what s best for patients.
CAR T-cell therapy showed efficacy in achieving complete responses among patients with relapsed or refractory CLL or SLL after BTKi and BCL2 inhibitor.
Deborah Stefanek s doctor recommended she take a new medication called Kisempta to treat her relapsing remitting multiple sclerosis. She was shocked to learn every province in Canada covers Kisempta under their Pharmacare plans except B.C.
? 2022 marks Ceapro's best performance in Company history with record sales of $18,800,000 compared to $17,200,000 for 2021, representing a 10% increase year over year ? Net profit after tax of $4,400,000 for the full year of 2022 compared to.